Linjeta regulatory update

FDA issued a complete response letter and requested 2 new clinical trials for diabetes candidate Linjeta. The agency asked the company to conduct a new trial in each of Linjeta's proposed indications - Type I and II diabetes - to establish efficacy and safety as related to hypoglycemia and toleration. ...